Loading...

Varex Imaging Corporation

VREXNASDAQ
Healthcare
Medical - Devices
$11.57
$0.23(2.03%)

Varex Imaging Corporation (VREX) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for Varex Imaging Corporation (VREX), covering cash flow, earnings, and balance sheets.

Revenue Growth
-9.22%
9.22%
Operating Income Growth
-58.37%
58.37%
Net Income Growth
-198.96%
198.96%
Operating Cash Flow Growth
-56.37%
56.37%
Operating Margin
-4.44%
4.44%
Gross Margin
34.06%
34.06%
Net Profit Margin
-16.13%
16.13%
ROE
-25.48%
25.48%
ROIC
-4.07%
4.07%

Varex Imaging Corporation (VREX) Income Statement & Financial Overview

Analyze Varex Imaging Corporation’s VREX earnings with segmented quarterly and yearly financial statement figures.

MetricQ2 2025Q1 2025Q4 2024Q3 2024
Revenue$212.90M$199.80M$205.70M$209.10M
Cost of Revenue$136.20M$131.30M$138.60M$142.20M
Gross Profit$76.70M$68.50M$67.10M$66.90M
Gross Profit Ratio$0.36$0.34$0.33$0.32
R&D Expenses$22.00M$23.50M$21.90M$22.00M
SG&A Expenses$32.60M$33.80M$34.30M$35.60M
Operating Expenses$54.60M$57.30M$56.20M$57.60M
Total Costs & Expenses$190.80M$188.60M$194.80M$199.80M
Interest Income$2.90M$2.10M$1.80M$1.80M
Interest Expense$10.40M$8.20M$7.80M$7.60M
Depreciation & Amortization$6.60M$7.10M$6.60M$7.00M
EBITDA$22.10M$17.80M$16.90M$16.30M
EBITDA Ratio$0.10$0.09$0.08$0.08
Operating Income$22.10M$11.20M$10.90M$9.30M
Operating Income Ratio$0.10$0.06$0.05$0.04
Other Income/Expenses (Net)-$11.30M-$8.70M-$8.40M-$8.50M
Income Before Tax$10.80M$2.50M$2.50M$800000.00
Income Before Tax Ratio$0.05$0.01$0.01$0.004
Income Tax Expense$3.70M$2.60M$52.40M-$700000.00
Net Income$6.90M-$300000.00-$50.00M$1.40M
Net Income Ratio$0.03-$0.002-$0.24$0.007
EPS$0.17-$0.007-$1.23$0.03
Diluted EPS$0.17-$0.007-$1.23$0.03
Weighted Avg Shares Outstanding$41.40M$41.10M$40.80M$40.90M
Weighted Avg Shares Outstanding (Diluted)$51.20M$41.10M$40.80M$41.20M

Over the past four quarters, Varex Imaging Corporation demonstrated steady revenue growth, increasing from $209.10M in Q3 2024 to $212.90M in Q2 2025. Operating income reached $22.10M in Q2 2025, maintaining a consistent 10% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $22.10M, reflecting operational efficiency. Net income rose to $6.90M, with EPS at $0.17. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;